Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Past 24 hours
Any time
Past hour
Past 7 days
Past 30 days
Best match
Most recent
23h
Goldman Sachs Remains a Sell on Exelixis (EXEL)
In a report released yesterday, Chris Shibutani from Goldman Sachs maintained a Sell rating on Exelixis (EXEL – Research Report). The ...
Parade on MSN
19h
'I Was Diagnosed With a Rare Genetic Condition At 20—These Are the First Symptoms I Noticed'
S ean Korbitz was a 20-year-old college student when he first started experiencing symptoms of von Hippel-Lindau syndrome, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
One Direction singer dies
Gets minimum 28 years
US Navy aircraft crashes
US adults loneliness survey
Exotic cat caught in suburb
Parents sue MA school
Felon voting rights upheld
To return to Atlanta in 2028
Had benign cyst removed
Salton Sea conservation
Disney to debut new pass
Cereal dyes protested
Broadband data caps probe
MI shooter drill settlement
SpaceX sues CA regulators
To invest in nuclear reactors
To headline Atlanta rally
$750M US chips grant
$1.4B renovation deal OK'd
Ordered to pay $15 million
'Click to cancel' finalized
Italy expands surrogacy ban
Synthetic nicotine pouches
New cervical cancer regimen
FDA halts Novavax trial
To cut up to 2,500 jobs
Abortion group sues Florida
To settle US bribery probe
21K+ SUVs recalled
$425M military aid for UKR
Related topics
Exelixis
Merck & Co.
zanzalintinib
Pembrolizumab
Feedback